Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2012
07/05/2012WO2012089762A1 Cetyl myristate and/or cetyl palmitate granules having high bulk density
07/05/2012WO2012089761A1 Controlled moisture content of cetyl myristate and/or cetyl palmitate granules or formulations
07/05/2012WO2012089759A1 Formulations of cetyl myristate and/or cetyl palmitate particles
07/05/2012WO2012089738A1 A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
07/05/2012WO2012089729A1 Improved powderous vitamin e formulations
07/05/2012WO2012089677A1 Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
07/05/2012WO2012089633A1 Novel pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
07/05/2012WO2012089623A1 Topical localized isoxazoline formulation comprising glycofurol
07/05/2012WO2012089622A2 Topical localized isoxazoline formulation
07/05/2012WO2012089607A1 Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
07/05/2012WO2012089606A1 Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
07/05/2012WO2012089602A1 Small molecule conjugates for intracellular delivery of biologically active compounds
07/05/2012WO2012089601A1 New biaryl amide derivatives
07/05/2012WO2012089593A1 Method of preparing polymorphic pure form a of bazedoxifene acetate
07/05/2012WO2012089352A1 Small molecule conjugates for intracellular delivery of nucleic acids
07/05/2012WO2012089256A1 Medicated patch for improved transdermal permeation of diclofenac diethylammonium
07/05/2012WO2012089220A1 Method for producing a water-soluble medicinal form of an antibiotic from the group consisting of rifamycins, and composition produced by said method
07/05/2012WO2012089180A1 Form c of prasugrel hydrobromide and a method for its production
07/05/2012WO2012089137A1 Arylurea compound, intermediate and use thereof
07/05/2012WO2012089127A1 Certain dipeptidyl peptidase inhibitors
07/05/2012WO2012089123A1 Certain dipeptidyl peptidase inhibitors
07/05/2012WO2012089122A1 Certain dipeptidyl peptidase inhibitors
07/05/2012WO2012089106A1 Aromatic alkyne derivative as protein kinase inhibitor and medical use thereof
07/05/2012WO2012089058A1 Crystalline form of ertapenem sodium and preparation method therefor
07/05/2012WO2012089053A1 Method for inhibiting myopia and use of adenylate cyclase inhibitor as drug for inhibiting myopia
07/05/2012WO2012089051A1 Benzopyrone estrogen receptor regulator
07/05/2012WO2012088885A1 Total flavonoid extract of fructus aurantii immaturus or fructus aurantii, and use thereof
07/05/2012WO2012088777A1 Effective part of ginseng, preparing method and use thereof
07/05/2012WO2012088712A1 Compound as wnt signaling inhibitor, composition, and use thereof
07/05/2012WO2012088682A1 2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
07/05/2012WO2012088680A1 Certain dipeptidyl peptidase inhibitors
07/05/2012WO2012088677A1 Certain dipeptidyl peptidase inhibitors
07/05/2012WO2012088647A1 Deuterated acid addition salt of sitaliptin
07/05/2012WO2012088597A1 Nitric oxide amino acid esters for enhancement of physical or muscular performance and the treatment of muscular or neuromuscular diseases
07/05/2012WO2012067868A3 Coloring composition containing l-dopa and l-arginine and forming a non-covalent derivatization complex
07/05/2012WO2012065102A3 S-t-butyl protected cysteine di-peptide analogs and related compounds
07/05/2012WO2012064967A3 Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
07/05/2012WO2012064943A3 Metalloenzyme inhibitor compounds
07/05/2012WO2012064914A3 Peptidomimetic inhibitors of psma
07/05/2012WO2012064897A3 Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use
07/05/2012WO2012064396A9 Novel ezrin inhibitors and methods of making and using
07/05/2012WO2012061820A9 Materials and methods for treating radiation poisoning
07/05/2012WO2012061402A3 System and method for delivery of dna-binding chemotherapy drugs using nanoparticles
07/05/2012WO2012058268A3 Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
07/05/2012WO2012055573A8 Use of hepcidin binding nucleic acids for depletion of hepcidin from the body
07/05/2012WO2012055567A3 Use of malononitrilamides in neuropathic pain
07/05/2012WO2012054923A3 Therapeutic nanoparticles with high molecular weight copolymers
07/05/2012WO2012054742A3 Implantable polymer for bone and vascular lesions
07/05/2012WO2012054723A3 Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
07/05/2012WO2012054110A3 Compounds and methods for inhibiting phosphate transport
07/05/2012WO2012052479A3 Brimonidine gel compositions and methods of use
07/05/2012WO2012051614A3 Delivery of hydrophobic bioactive agents
07/05/2012WO2012051313A3 Ophthalmic formulations, methods of manufacture and methods of normalizing meibomian gland secretions
07/05/2012WO2012050641A3 Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents
07/05/2012WO2012049227A3 Novel omega-3 and omega-6 fatty acid compositions and uses thereof
07/05/2012WO2012047926A3 Sulfonamide-containing compounds
07/05/2012WO2012045083A9 Minimizing intestinal dysfunction
07/05/2012WO2012044963A3 Perfluorocarbons for use in treating pruritus
07/05/2012WO2012044139A3 Novel use of cryptotanshinone
07/05/2012WO2012040707A3 Materials and methods for improving gastrointestinal function
07/05/2012WO2012040623A3 Nanostructured gels capable of controlled release of encapsulated agents
07/05/2012WO2012040527A3 Deubiquitinase inhibitors and methods for use of the same
07/05/2012WO2012038989A3 Calcium fortifying composition for strength, a hydration supplement, and process for preparing the same
07/05/2012WO2012038945A3 Control of mites
07/05/2012WO2012037553A9 Use of pkc-iota inhibitors for the treatment of breast cancer
07/05/2012WO2012037411A3 Estrogen receptor modulators and uses thereof
07/05/2012WO2012035480A3 Pharmaceutical compositions of curcumin
07/05/2012WO2012033525A3 P53-mdm2 antagonists
07/05/2012WO2012032523A3 Compositions comprising acidic extracts of mastic gum
07/05/2012WO2012032509A3 Conjugates of polyunsaturated fatty acids and amine-containing compounds and uses thereof
07/05/2012WO2012031220A3 Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
07/05/2012WO2012031028A3 Methods for treating neurodegenerative diseases
07/05/2012WO2012030919A3 Composition and method for muscle repair and regeneration
07/05/2012WO2012030513A3 Methods of treating bacterial infections through pulmonary delivery of fusidic acid
07/05/2012WO2012030165A3 Use of the fetal reprogramming of a ppar δ agonist
07/05/2012WO2012028966A3 Combination dosage compositions comprising a cholesterol-lowering agent, a renin-angiotensin system inhibitor, an antioxidant agent and an antiplatelet agent for treatment and prevention of cardiovascular disease
07/05/2012WO2012026988A3 Dendrimeric peptides, pharmaceutical compositions and methods of using the same
07/05/2012WO2012024558A3 Light mediated regulation of protein dimerization
07/05/2012WO2012018949A3 Compositions and methods for the treatment of cancer
07/05/2012WO2012011741A9 Novel fusarisetin compounds, and use thereof
07/05/2012WO2012009402A3 Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
07/05/2012WO2011162480A9 Composition for treating prion diseases comprising hif-1α agonist
07/05/2012WO2011156361A3 Solid dispersions containing kinase inhibitors
07/05/2012WO2011151461A3 Autotaxin pathway modulation and uses thereof
07/05/2012WO2011128633A3 Oral pharmaceutical dispersion compositions
07/05/2012WO2011124245A3 Microbiologically stable, easily applicable preparations comprising anionic or cationic active substances
07/05/2012WO2011124241A3 Microbiologically stable, easily applicable preparations
07/05/2012WO2011110876A8 Novel salts for the manufacture of pharmaceutical compositions
07/05/2012WO2011085643A8 Fused pyridine derivatives
07/05/2012WO2011084366A3 Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions
07/05/2012WO2011082337A8 Therapeutic compounds and related methods of use
07/05/2012WO2011061754A9 A novel 3-substituted 7-imino-2-thioxo-3, 7-dihydro-2h-thiazolo [4,5-di pyrimidin-6-yl - and process for preparation thereof
07/05/2012WO2011031816A3 Histamine h3 inverse agonists and antagonists and methods of use thereof
07/05/2012WO2011010174A8 Crystalline form i rosuvastatin zinc salt
07/05/2012WO2009064387A3 C4 ' - substituted- 2 ' - deoxyadenosine analogs and methods of treating hiv
07/05/2012US20120174260 Nucleic acid molecules that target the rho1 small gtp-binding protein and confer resistance to coleopteran pests
07/05/2012US20120174259 Nucleic acid molecules that target the vacuolar atpase c subunit and confer resistance to coleopteran pests
07/05/2012US20120174244 Profiling fragments of elastic fibers and microfibrils as biomarkers for disease
07/05/2012US20120174243 SOGA Polynucleotides and Polypeptides and Uses Thereof
07/05/2012US20120172808 Stable Bortezomib Formulations
1 ... 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 ... 7860